BindingDB logo
myBDB logout

21 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25757604 2 (18)F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging.EBI BC Cancer Agency
23992105 4 Studies toward the development of new silicon-containing building blocks for the direct (18)F-labeling of peptides.EBI Institute of Technology (ETH) Zurich
23265893 7 Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.EBI The Ohio State University
18329268 2 Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate.EBI Universit£ de Sherbrooke
9873586 50 PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.EBI Cambridge University Forvie Site
 42 PD 165929 the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonistEBI TBA
24900253 28 Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityEBI TBA
20219372 114 Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.EBI Merck Research Laboratories
20167483 90 Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.EBI Merck Research Laboratories
19553112 39 Discovery and optimization of a novel Neuromedin B receptor antagonist.EBI Amgen Inc
 2 CP-70,030 and CP-75,998: The first non-peptide antagonists of bombesin and gastrin releasing peptideEBI TBA
19522464 3 Structural assessment and biological evaluation of two N3S bombesin derivatives.EBI Institutes of Radioisotopes-Radiodiagnostic Products and Biology
18818070 28 Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.EBI GlaxoSmithKline
15634004 20 Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.EBI National Center for Scientific Research Demokritos
12723954 47 Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.EBI Technische Universität München
11985468 21 Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.EBI Washington University
10882361 18 Synthesis and biological evaluation of bombesin constrained analogues.EBI University of Montpellier
8120863 47 Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues.EBI Burroughs Wellcome Company
2066982 42 Gastrin releasing peptide antagonists with improved potency and stability.EBI Merck Sharp & Dohme Research Laboratories
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
10353842 147 Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).BDB National Institute of Diabetes and Digestive and Kidney Diseases